Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-176 in Advanced Solid Tumors
NCT03145909Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of rolinsatamab talirine in breast cancer, colorectal cancer (CRC), adrenocortical carcinoma (ACC) and 1 more (2 cohorts), sponsored by AbbVie Inc. Primary endpoints: Time to Maximum Plasma Concentration (Tmax) at 57 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC∞) at 57 days and 7 more. Started Jul 2017; status: terminated.
02
Drugs
rolinsatamab talirine
03
Conditions
breast cancercolorectal cancer (CRC)adrenocortical carcinoma (ACC)chromophobe renal cell carcinoma (chRCC)
Beyond the preview
Go deeper on NCT03145909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145909.